AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

PRCT · NASDAQ · Medical - Devices

PROCEPT BioRobotics (PRCT)

Robotic platform for autonomous, heat-free waterjet ablation of prostate tissue.

$22.13

Pre-market+0.15 (+0.68%)

At close$21.98(+5.12%)

Watchlist

In millions of USD, except per-share figures

In millions	Q3 FY23Sep 2023	Q4 FY23Dec 2023	Q1 FY24Mar 2024	Q2 FY24Jun 2024	Q3 FY24Sep 2024	Q4 FY24Dec 2024	Q1 FY25Mar 2025	Q2 FY25Jun 2025	Q3 FY25Sep 2025	Q4 FY25Dec 2025	Q1 FY26Mar 2026	Q2 FY26Jun 2026
Revenue	35	44	45	53	58	68	69	79	83	76	83	94
Cost of revenue	16	22	20	22	21	25	25	29	31	30	29	32
Gross profit	19	21	25	31	37	44	44	50	52	46	54	62
	44	51	53	58	59	63	72	72	76	77	87	90
Research & development	12	14	13	18	17	15	16	16	17	19	21	20
Selling, general & administrative	33	36	40	41	43	48	55	56	59	58	65	70
Other expenses	0	0	0	0	0	0	0	0	0	0	0	0
Operating income	−26	−30	−28	−27	−22	−20	−27	−22	−23	−31	−33	−27
	1	2	2	1	1	1	3	3	2	1	1	1
Interest income	2	3	3	2	3	3	4	4	3	2	2	1
Interest expense	1	1	1	1	1	1	1	1	1	1	1	1
Other non-operating income	−2	−3	−3	−2	−3	−2	−4	−4	−3	−2	−2	−1
Income before tax	−25	−28	−26	−26	−21	−19	−25	−20	−21	−30	−32	−27
Income tax expense	0	0	0	0	0	0	0	0	0	0	0	0
Net income from continuing operations	−25	−28	−26	−26	−21	−19	−25	−20	−21	−30	−32	−27
Net income	−25	−28	−26	−26	−21	−19	−25	−20	−21	−30	−32	−27
EPS, basic	−$0.51	−$0.54	−$0.51	−$0.50	−$0.40	−$0.35	−$0.45	−$0.35	−$0.38	−$0.53	−$0.56	−$0.47
EPS, diluted	−$0.51	−$0.54	−$0.51	−$0.50	−$0.40	−$0.35	−$0.45	−$0.35	−$0.38	−$0.53	−$0.56	−$0.47
Weighted average shares, basic	48	51	51	52	52	54	55	55	56	56	57	57
Weighted average shares, diluted	48	51	51	52	52	54	55	55	56	56	57	57
EBITDA	−23	−25	−24	−23	−19	−16	−22	−17	−19	−27	−29	−24
Depreciation & amortization	1	1	1	1	1	1	1	2	2	2	2	2
EBIT	−24	−26	−25	−25	−20	−18	−24	−19	−20	−29	−31	−26